患者自付费用与GLP-1RA依从性及不良健康结局的关联
这项回顾性队列研究利用2016-2021年MarketScan商业数据库,纳入61,907例起始GLP-1RA治疗的2型糖尿病成人。结果显示,较高的30天自付费用与依从性降低相关,而不依从与糖尿病相关住院或急诊就诊率、全因急诊就诊率及费用增加相关。
要点
- 最高自付费用四分位组(80-3,375美元)不依从的比值比为1.25(95%CI 1.19-1.31),对照为最低组(0-21美元)。
- 不依从与糖尿病相关住院或急诊就诊发生率升高相关(IRR 1.86;95%CI 1.43-2.42)。
- 不依从还与全因急诊就诊率升高(IRR 1.38;95%CI 1.32-1.45)及急诊相关费用增加(69.81美元;95%CI 53.54-86.08)相关。
核心结论
- 较高的GLP-1RA自付费用与2型糖尿病患者依从性降低及不良结局发生率增加相关。
研究设计与样本
- 回顾性队列研究,使用MarketScan商业数据(2016-2021年),纳入18-64岁非妊娠2型糖尿病成人,起始GLP-1RA治疗,并在处方日期前6个月及后1年连续参加同一私人保险计划,共61,907例。
主要发现
- 最高自付费用四分位组(Q4:80-3,375美元)与最低组(Q1:0-21美元)相比,不依从的比值比为1.25(95%CI 1.19-1.31)。
- 不依从与糖尿病相关住院或急诊就诊发生率升高相关(IRR 1.86;95%CI 1.43-2.42)。
- 不依从与累计住院时长增加相关(IRR 1.56;95%CI 1.41-1.72)。
- 不依从与全因急诊就诊率升高相关(IRR 1.38;95%CI 1.32-1.45),并与急诊相关费用增加69.81美元(95%CI 53.54-86.08)相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the associations between patient out-of-pocket (OOP) costs and nonadherence to glucagon-like peptide 1 receptor agonists (GLP-1RA), and the consequent impact on adverse outcomes, including hospitalizations and emergency department (ED) visits. RESEARCH DESIGN AND METHODS: This retrospective cohort study used MarketScan Commercial data (2016-2021). The cohort included nonpregnant adults aged 18-64 years with type 2 diabetes who initiated GLP-1RA therapy. Participants were continuously enrolled in the same private insurance plan for 6 months before the prescription date and 1 year thereafter. Exposures included average first 30-day OOP costs for GLP-1RA, categorized into quartiles (lowest [Q1] to highest [Q4]). Primary outcomes were the annual proportion of days covered (PDC) for GLP-1RA and nonadherence, defined as PDC <0.8. Secondary outcomes included diabetes-related and all-cause hospitalizations and ED visits 1 year after GLP-1RA initiation. RESULTS: Among 61,907 adults who initiated GLP-1RA, higher 30-day OOP costs were associated with decreased adherence. Patients in the highest OOP cost quartile (Q4: $80-$3,375) had significantly higher odds of nonadherence (odds ratio [OR] 1.25; 95% CI 1.19-1.31) compared with those in Q1 ($0-$21). Nonadherence was linked to increased incidence rates of diabetes-related hospitalizations or ED visits (incidence rate ratio [IRR] 1.86; 95% CI 1.43-2.42), cumulative length of hospitalization (IRR 1.56; 95% CI 1.41-1.72), all-cause ED visits (IRR 1.38; 95% CI 1.32-1.45), and increased ED-related costs ($69.81, 95% CI $53.54-$86.08). CONCLUSIONS: Higher OOP costs for GLP-1RA were associated with reduced adherence and increased rates of adverse outcomes among patients with type 2 diabetes.
引用
- Zhang D, Gencerliler N, Mukhopadhyay A, et al. Association of Patient Cost Sharing With Adherence to GLP-1RA and Adverse Health Outcomes. Diabetes Care. 2025. PMID: 40202527. doi:10.2337/dc24-2746
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。